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Oral Presentations S167MNCs for 7d in RPMI-1640 + 10 IU IL-2. NKR expression
(KIR2DS4, NKG2D, NKG2A, CD94, KIR3DL1, KIR3DL2,
Nkp46), LAMP-1 receptor expression and NK cell phenotype
(CD56dim/bright subsets) determined by flow cytometry. On Day 0,
CD3-/56+ NK cell subset was 3.06 1.3%. After 7d culture, NK cells
increased to 71.76 3.9%, compared tomedia alone (9.76 2.4%) and
WTK562 (42.66 5.9%,p\0.01). This represented a 35-fold or
33746 385% increase of input NK cell number. CB Tcells were
decreased compared to media alone and WTK562 (15.16 1.7 vs
516 7.1 vs 35.76 2.4%,p\0.001). CD56bright vs CD56dim subsets
were increased (67 vs 33%,p\0.01) following K562-mbIL15-
41BBL stimulation. CB NK cells expressing KIR3DL1 were
increased 10-fold following stimulation with K562-mbIL15-41BBL
vsWTK562 (p\0.01) and 5-fold increase in NK KIR2DS4 expres-
sion (p\0.05), respectively. NK activation marker, CD107a was in-
creased compared to WTK562 (516 0.7 vs 326 1.1%, p\0.05).
Since a standard cryopreserved UCB unit contains approximately
75107 MNCs, by using the smaller aliquot (5 ml or 20%)
150106 MNCs x 3.9%5 5.8106NK cells, this method may yield
2.0108 CB NK cells after 7d culture. This suggests that CBMNC
can be expanded by K562-mbIL15-41BBL resulting in increased
NK cell KIR expression (KIR2DS4, KIR3DL1) and NK activation
(CD107a) with a decrease in T cells which may provide a means to
enhance specific CB NK expansion for ACI in post UCBT setting.33
VIABILITY AND POTENCY OF HEMATOPOIETIC PROGENITOR CELLS AF-
TER PROLONGED CRYOPRESERVATION AT -80 C
Khattab, M., Gilmore, G.L., Sahovic, E.A., Miller, S.M., Rossetti, J.M.,
Abdulhaq, H., Lister, J. The Western Pennsylvania Cancer Institute,
Pittsburgh, PA
Hematopoietic progenitor cell (HPC) products cryopreserved in
the liquid or vapor phase of liquid nitrogen (LN) remain viable
and potent for years. Cryopreserved HPC products when stored at
-80 C inmechanical freezers are known to remain viable and potent
for up to 180 days. We demonstrated viability and potency of HPC
products stored at -80 C for up to 12 years. Products were cryopre-
served in 6% hydroxyethyl starch, 5%DMSO and 4% human serum
albumin using non-controlled rate freezing.
Thawed products were tested for viability and potency respec-
tively by trypan blue dye exclusion and hematopoietic progenitor
cell colony assay (CFU-GM, BFU-E, CFU-GEMM). All culture as-
says used MethoCult GF+ H4445 (STEMCELL Technologies,
Vancouver, BC, Canada).
We thawed 20HPC products collected frommobilized peripheral
blood. The products were stored between 7 and 12 years at -80 C.
In 19 cases, trypan blue dye exclusion yielded an average 72% viabil-
ity (range: 50%-89%). HPC colony assay yielded average progenitor
frequencies of: CFU-GM159 [range: 15-600]; BFU-E 116 [range: 2-
388] and CFU-GEMM 21 [range: 2-68] all per 105 viable cells
plated. The average values did not differ from control values of
CFU-GM 111, BFU-E 121 and CFU-GEMM 23. Two products
were infused into their donors after myeloablative conditioning,
UPN947 andUPN1000. The products were stored for over 9 years.
The products fromUPN947/UPN1000 gave 73%/65%viability by
trypan blue dye exclusion, CFU-GM 347/508, BFU-E 135/344,
CFU-GEMM 12/48 per 105 viable cells, ANC500 day + 14/
day + 11 and PLT50 day + 15/day + 24.
We conclude that viability and potency of these HPC products
flash-frozen and stored at -80 C in pentastarch is maintained for
up to 12 years. In two cases engraftment was achieved with long-
term cryopreserved products. The data suggest that prolonged cryo-
preservation of HPC products using LN may not be necessary to
preserve product potency.
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DEVELOPMENT OF THE ‘‘MARROWMINER’’: A NOVEL, MINIMALLY INVA-
SIVE DEVICE OF FOR THE HARVEST OF BONE MARROW. FROM BENCH-
TOP, TO ANIMAL STUDIES, THROUGH FDA APPROVAL AND HUMAN
EVALUATION
Kraft, D.1, Crocker, M.2, Ghazarossian, V.2, Antonio, C.A.3 1Stanford
University, Stanford, CA; 2StemCor Systems Inc,Menlo Park, CA; 3San-
gre De Cordon SA, Guadalajara, MexicoBonemarrow (BM) is the traditional graft source in hematopoietic
stem cell transplantation. An increasing body of work suggests that
use of BM grafts may show long-term advantages over mobilized
PBSC in some alloegeneic transplant settings, resulting in signifi-
cantly less cGVHD, morbidity and improved survival. Traditional
OR based BM harvest methods however remain crude, labor and re-
source intensive, generally requiring full general anesthesia, 2 trans-
plant clinicians, 100+ serial small volume needle aspirates, and result
in grafts highly diluted by peripheral blood. Improved harvest
methods are needed.
To address the need to develop improved methods for harvest,
The ‘‘MarrowMiner’’ (MM) was conceived. The MarrowMiner
(MM), is a novel, now FDA cleared & CE-Marked device developed
for the minimally invasive harvest of BM to enable the rapid, conve-
nient, outpatient harvest of large quantities of BM via a single mar-
row entry site, under local anesthesia. A powered, rotating FlexShaft
enables the clinician to access a broad area of the ileac marrow space
through a single cortical bone entry site trocar. The FlexShaft moves
through the cancellous bone, without puncturing the cortical wall,
while aspirating rich marrow under negative pressure into a closed
container.
Preclinical trails in porcine models compared the marrow har-
vested with the MM to standard 6-hole harvest in the opposite ileac.
This 6 pig study revealed a significantly richer bonemarrow with.9
foldColony Forming (CFU-F) perml compared to standard harvest.
Following FDA approval, successful ‘First in Man’ studies were con-
ducted demonstrating safety and efficacy in patients having marrow
harvested for regenerative medicine studies.
A 21 patient trial comparing the MM to standard harvest. The
MARVELOUS (MARrowMiner VErsus standard ILeac bOne
marrow pUncture and aSpiration)) study found that MM aspirate
(performed under local anesthesia) had a greater average TNC
count/ml compared to standard marrow harvest in the same patient,
with equivalent viability. Higher numbers of %ALDH+, CD34+,
phenotypic MSC) were obtained by MM.
The novel MM system demonstrated safety and efficacy in
clinical use. An ongoing trial is evaluating the MM in the BMT set-
ting, and a commercial version of the device is nearing production.
The MM device device may benefit ease of harvest for donors,
clinicians and could ultimately lead to better outcomes for trans-
plant recipients.35
DETECTION AND EX VIVO EXPANSION OF DORMANT ANTI-VIRAL CTL
PRECURSORS ISOLATED FROM RECIPIENTS OF UNRELATED UMBILICAL
CORD BLOOD TRANSPLANT (UCBT)
Marti, L.C.1, Leen, A.M.2, Janetzki, S.3, Baker, J.H.1, Szabolcs, P.4
1Duke University Medical Center, Durham, NC; 2Baylor College of
Medicine, Houston, TX; 3Zellnet Consulting, Fort Lee, NJ; 4Duke Uni-
versity Medical Center
Viral infections are commonly detected within weeks after UCBT
that could trigger in vivo priming of the infused naı¨ve T cells. This
hypothesis is supported by the observation that infections can resolve
without antiviral therapy.
Objectives: In this study we focused on two potentially fatal viruses,
CMV and adenovirus to assess the acquisition and evolution of anti-
gen-specific immunity. We hypothesized that 1) threshold numbers
of CTL precursors can be identified for each virus that may influence
outcome 2) CTL precursors may reside below the level of detection
duringGVHDprophylaxis, however, ex vivo restimulation could ex-
pand them to measurable frequencies.
Methods: Monocytes infected with an adenovirus vector carrying
the CMV pp65 transgene (Ad5f35pp65) were used as APC in the
presence of IL7. Antiviral CTLp was quantitated by ELISPOT
with computerized enumeration of IFNg producing spot forming
cells (SFC) in response to peptide pools spanning dominant viral an-
tigens: hexon and penton for adenovirus, pp65, EI-1 for CMV.
Results: 8 infected patients at a median age of 9.9 years have been
studied. Blood was drawn at a median of 70 days (range 34-470).
Only 1 of 3 patients with adenovirus infection (stool x1, urine x1,
respiratory tract x 1) had associated viremia while all five (5) patients
withCMVhadviremia.Analyzing freshlydrawnperipheral blood1of
S168 Oral Presentations3 adeno patients had detectable hexon-specific response (11 SFC/
110e5 cells), however, none of the 5 CMV+ patients had any
detectable SFC. However, after 9-12 days of stimulation we could
enumerate CTLp in 7/8 patients. For adenovirus, the median
hexon-specific response was 52 SFC/110e5 SFC (range 20-90),
and the penton-specific CTLp frequency was 13 SFC/110e5
(1 – 25). The median CMV pp65-specific response was 6.7 SFC/
110e5 (0-14).No responses were recorded against CMVEI-1 dem-
onstrating the critical role of antigenic restimulation by the
Ad5f35pp65 construct lacking IE. Smilarly in the adeno+/CMV-
patients we detected SFC solely against hexon and/or penton. All
patients are surviving at a median of 220 days after transplant (range
81-532).
Conclusion: To our knowledge these are the first data demonstrat-
ing that dormant virus-specific CTLp are present already in the first
2-3 months in most adenovirus or CMV infected UCBT recipients
(7/8 in this dataset). Although these rare events are below detection
by standard ELISPOT the feasibility of their ex vivo expansion may
lead to adoptive therapies.GVH/GVL
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COMMON COLD VIRUSES EARLY AFTER HSCT ARE ASSOCIATED WITH
LIFE THREATENING ALLOIMMUNE LUNG SYNDROMES
Versluys, A.B.1, Rossen, J.W.2, Ewijk, B.3, Schuurman, R.2,
Bierings, M.B.1, Boelens, J.J.1 1University Medical Center Utrecht,
Wilhelmina Children’s Hospital, Utrecht, Netherlands; 2Eijkman-
Winkler Center, University Medical Center, Utrecht, Netherlands; 3Uni-
versity Medical Center Utrecht, Wilhelmina Children’s Hospital, Utrecht,
Netherlands
In lung transplantation, early infection (\100 d) with a common
respiratory virus (RV) is associated with acute or chronic rejection,
presenting as Bronchiolitis Obliterans (BO). After hematopoietic
stem cell transplantation (HSCT) alloimmune lung syndromes
(allo-LS), including Idiopathic Pneumonia Syndrome (IPS; acute)
and BO (chronic), also occur, but the role of RV is unclear. In
this prospective cohort study we analyzed the influence of common
RV early (\ 100 days) after HSCT, on the development of allo-LS
and survival. 110 paediatric patients with a median age of 5 years (2
mths – 21years), were included. They received a transplant (56
matched, 54 mismatched; 33 cord blood, 77 bone marrow; 33 fam-
ily, 77 unrelated) for malignant (56) and non-malignant (54) dis-
ease, after a TBI (33) or chemotherapy based (77) conditioning
regimen. In 50% of patients a RV infection occurred, at a median
of day +16 (range -7 to 100). RV was proven by qPCR on nasopha-
ryngeal aspirate: Rhinovirus was found most frequent (28), fol-
lowed by Parainfluenzavirus1-3, Coronavirus, Influenza A virus
and Adenovirus. Clinical symptoms were mild, and all patients re-
covered spontaneously, despite the fact that the RV remained pres-
ent for months in all patients. After a period without symptoms of
at least 2 weeks, new respiratory symptoms occurred in about 50%
of the RV positive patients. Based on additional examinations
including negative cultures (other than RV), radiology and pulmo-
nary function tests, 30 patients (27.2%) were diagnosed with allo-
LS: 18 IPS (16.4%) and 12 BO (10.9%), after a median time of 8
weeks (2-26). Multivariable analysis showed that RV infection is
an important predictor for allo-LS (p\0.0001). There was no
difference between Rhinovirus versus all others. Acute Graft-
versus-Host Disease (aGVHD), occurring at a median of 4 weeks
(2-15), had a protective effect on the development of allo-LS
(p5 0.004), most likely due to higher and prolonged immunesup-
pression in these patients. Overall survival was 73%; in the allo-LS
group this was only 53%. In multivariable analysis allo-LS was the
only predictor for mortality (p5 0.04).
In conclusion, early presence of RV is a predictor for the develop-
ment of allo-LS.We hypothesise that infection with a common cold
virus makes the lung a target for alloimmunity, leading to life threat-
ening lung disease. Paradoxically, prolonged immune suppression,
despite the local viral infection, protected against the development
of allo-LS.37
RAPID RECONSTITUTION OF THE REGULATORY T CELL COMPARTMENT
AFTER HIGH DOSE CYCLOPHOSPHAMIDE IMMUNOSUPPRESSION PRE-
VENTS THE DEVELOPMENT OF GVHD AFTER ALLOGENEIC BMT
Hess, A.D., Fuchs, E.J., Luznik, L., Thoburn, C.J., Kos, F., Jones, R.J.
The Johns Hopkins University, Baltimore, MD
Graft-versus-host disease (GVHD) is a life-threatening complica-
tion of allogeneic bone marrow transplantation (BMT). Although
the development of immunosuppressive regimens has reduced the
incidence and severity of this post transplant complication, GVHD
continues to be a significant clinical problem. There is also signifi-
cant toxicity associated with the multi-agent immunosuppressive
regimens. Recent studies revealed that high dose cyclophosphamide
(Cy, 50 mg/kg) was effective at reducing the incidence of grades
II-IV GVHD when administered as a single agent on days 3 and 4
following HLAmatched related and unrelated BMT. The incidence
of chronic GVHD was also reduced to 10%. The present studies
evaluated the reconstitution of the CD4 +CD25 + Foxp3+ regula-
tory T cell compartment in patients treated with single agent high
dose Cy. Peripheral blood lymphocytes (50 patients) were harvested
on days 30, 45 and 60 post transplant and evaluated for Foxp3, IL-2
and IFN-g mRNA transcript levels by real time PCR and by enu-
meration of CD4 +CD25 + Foxp3 + T cells by flow cytometry.
The results reveal that there was an inverse correlation of Foxp3
mRNA transcripts with the incidence of grades II-IVGVHD.Levels
of Foxp3 mRNA transcripts in patients who did not develop GVHD
were .100 fold greater than the levels detected in patients who de-
veloped GVHD. Interestingly, mRNA transcript levels of IL-2 and
IFN-g were significantly increased (.100-1000 fold) in patients
developing acute GVHD. Additional studies revealed that CD4 +
CD25 + Foxp3 + T cells enumerated flow cytometrically in a subset
of patients (16) were also detected at significant levels (30-50 cells/
ul) as early as day 30 in patients who did not develop GVHD. Com-
paratively, the number of CD4 +CD25 + Foxp3 + T cells in patients
who developed acute GVHD was\10 cells/ul and remained persis-
tently low even at day 60. The peripheral blood mononuclear cells
were also assessed for T cell recombinant excision circles (TRECs)
as a marker for recent thymic emigrants. Surprisingly, TRECs
were not detected at day 30. Taken together, these results suggest
that there is a rapid recovery of CD4 +CD25 + Foxp3+ regulatory
T cells in the majority of patients treated with high dose Cy which
may prevent the development of GVHD. The absence of TRECs
in these patients may suggest that the expansion of the regulatory
compartment may be antigen driven from amature T cell population
or expanded by homeostatic mechanisms.38
PREVENTION OF ACUTE GVHD DURING MHC HAPLOIDENTICAL HSCT:
EVALUATING THE EFFICACY OF T-CELL COSTIMULATION BLOCKADE US-
ING A NOVEL RHESUS MACAQUE TRANSPLANT MODEL
Miller, W.3, Wheeler, C.1, Panoskaltsis-Mortari, A.2, Kirk, A.D.2,
Larsen, C.P.2, Blazar, B.R.3, Kean, L.S.1 1Emory University School of
Medicine, Atlanta, GA; 2University of Minnesota, Minneapolis, MN;
3Emory University School of Medicine, Atlanta, GA
Introduction:Despite the inadequacy of currentGvHDprophylaxis
for MHC-mismatched HSCT, the introduction of novel therapeu-
tics has been slow, likely due to the lack of a suitable translational
model to rigorously test emerging therapies.Herewedescribe anovel
Rhesusmacaquemodel,whichhas allowedus to evaluatemechanisms
controlling GvHD and its protection in a primate translational sys-
tem.
Methods: Using microsatellite-based MHC haplotyping, we devel-
oped the first MHC-defined primate HSCT system. HSCT recipi-
ents, prepared with 8 Gy TBI, received either no
immunosuppression or a costimulation blockade-based regimen
which included CD28 blockade (abatacept), CD40 blockade (with
the anti-CD40 antibody 3A8) and sirolimus after MHC haploident-
ical sibling HSCT. Recipients received a TNC dose of 9.3 +/-
2.7108/kg and a CD3+ cell dose of 1.1 +/- 0.88  108/kg.
Results: Three control recipients (no immunosuppression) demon-
strated rapid and complete donor engraftment, with T cell activation
and proliferation occurring by Day 7, coincident with the onset of
severe clinical GvHD. Flow cytometric analysis showed loss of
